OTHER APPROACHES TO GUIDELINE DEVELOPMENT
5. OTHER APPROACHES TO GUIDELINE DEVELOPMENT
Unfortunately, old habits die hard and many clinicians or organisations persist with supporting nonstandardised ad hoc statements or reviews, usually from expert bodies—this undesirable methodology or GOBSAT (Good Old Boys Sat Around a Table) should no longer be valid or encouraged (Miller and Petrie, 2000). These discussions are based on received wisdom, clinical judge- ment, and experience rather than current scientific evidence; lack an explicit decision-making process; and may be biased by undeclared conflicts of inter- est (Miller and Petrie, 2000). A good example of this was the guidelines for improving the use of antimicrobial agents in hospitals—a statement by the Infectious Diseases Society of America (IDSA) published in 1988 (Marr et al., 1988). Although commendable in their efforts at aiming to promote good qual- ity prescribing and that it remains a well-respected document, the development process was not evidence based as it was drafted by three authors with subse- quent review by 43 multidisciplinary members of the IDSA. Other deficien- cies of this document were the rather unhelpful format, lack of summary of the evidence, and no linkage of this to the ultimate recommendations. This chapter highlights a typical example of development methodological flaw before appreciation of EBM methodology became widespread.
“Consensus”-based statements (Murphy et al., 1998) are popular and involve a broad-based panel which listens to the scientific data presented by experts, weighs the information, and then composes a consensus statement that addresses a set of questions previously posed to the panel. Once again within a relatively small group, the interactions are such that some members will have a significant impact on the overall decisions. Other sources of bias
UK Guidelines: Methodology and Standards of Care
27 include the type of questions set, the composition of the panel, and the selec-
tion of the experts and literature. Examples of such a process is the consensus panel recommendations for managing serious candidaemia (Edwards et al., 1997), or synthesising a consensus strategy for combating the prevention and control of antimicrobial resistance microorganisms in hospitals (Goldman et al., 1996). The latter document is worthy of recognition as a good consensus statement—it aims to synthesise a strategy from expert opinion, experience, and key existing evidence. It is explicit in its intention and development process and recognises its inherent deficiencies. This document is widely acknowledged as pivotal in the process of building a subsequent evidence-based approach to preventing antimicrobial resistance in hospitals. This is recognised in the sub- sequent guidelines on this subject by the Society for Healthcare Epidemiology of America (SHEA) and the IDSA Joint Committee on the Prevention of Antimicrobial Resistance (Shlaes et al., 1997). This approach, although valu- able, does not follow the AGREE or SIGN developmental methodology. When the AGREE Instrument for appraising the quality of this guideline is applied to this report (www.agreecollaboration, June 2001), one identifies a number of deficiencies in the areas of stakeholder involvement, rigour of development, and clarity of presentation. This guideline takes much more the form of a specialist but not systematic review, with only one table presented linking four recommendations to evidence. Greater uniformity with AGREE by such North American approach to guidelines would be welcomed. A more struc- tured consensus approach to gathering expert opinion is the classic delphi panel. This technique has merits in that the process is structured, has a number of stages that lead ultimately to a convergence of opinion, and is coordinated by a central person who summarises and feeds the information back from the panel whose responses are anonymous (Evans, 1999).
Parts
» Antibiotic Policies: Theory and Practice
» THEORIES OF FACILITATING CHANGE
» OTHER APPROACHES TO GUIDELINE DEVELOPMENT
» QUALITY ASSURANCE AND DEVELOPMENT OF STANDARDS
» DEVELOPMENT OF CLINICAL STANDARDS IN SCOTLAND
» WHICH QI INTERVENTIONS HAVE BEEN STUDIED IN CAP?
» LINKING PROCESS OF CARE TO OUTCOMES IN QI
» WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE PROCESS OF CARE IN CAP?
» WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE OUTCOMES IN CAP?
» Designing and implementing a CAP intervention
» LEVEL OF AGGREGATION OF ANTIMICROBIALS
» ANTIMICROBIAL USAGE MEASURES
» Relationships based on patient-specific data
» Relationships based on aggregate usage
» ANTIBIOTIC CONSUMPTION; ALTERNATIVE UNITS OF MEASUREMENT
» ANTIBIOTIC CONSUMPTION CALCULATOR
» BENCHMARKING FOR REDUCING VANCOMYCIN USE AND VANCOMYCIN- RESISTANT ENTEROCOCCI IN US ICU S
» THE HARVARD EMERGENCY DEPARTMENT QUALITY STUDY
» ANALYSIS BY INDIVIDUAL ANTIMICROBIAL AGENT
» BENCHMARKING WITH OTHER ANTIMICROBIAL UTILISATION DATA
» STATE OF THE ART OF ANTIBIOTIC PROPHYLAXIS IN SURGERY
» AUDITING AND IMPROVING THE QUALITY OF ANTIBIOTIC PROPHYLAXIS IN SURGERY
» TYPES OF STUDIES TO OBTAIN QUALITY DATA ON A PATIENT LEVEL
» MULTIDISCIPLINARY ANTIMICROBIAL MANAGEMENT TEAMS
» THE ROLE OF THE PHARMACIST IN INFECTION MANAGEMENT
» TRAINING AND SUPPORT IN INFECTION MANAGEMENT FOR PHARMACISTS
» ANTIBIOTIC POLICY IN THE TERTIARY CARE CENTRE
» ANTIBIOTIC CONSUMPTION IN ICU S
» ANTIBIOTIC RESISTANCE IN ICU
» The impact of antibiotic policies and antibiotic consumption on antibiotic resistance
» IT and benchmarking to improve antibiotic prescribing
» COST OF HOSPITAL-ACQUIRED INFECTION
» THE COST OF ANTIMICROBIAL RESISTANCE
» Costs of screening/surveillance cultures
» Isolation, cohorting, and contact isolation
» EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS
» Antifungal resistance in Candida species
» Antifungal resistance cannot be transmitted by extrachromosomal DNA
» RATIONAL USE OF ANTIFUNGAL AGENTS
» THE CHANGING FACE OF VIRAL INFECTIONS AND THEIR MANAGEMENT
» PROBLEMS ASSOCIATED WITH ANTIVIRAL THERAPY
» ANTIVIRAL TREATMENT STRATEGIES
» ANTIVIRAL PROPHYLAXIS STRATEGIES
» ANTIBIOTIC CONCENTRATIONS AT TARGET SITES
» An infant with aplastic anaemia
» A long-standing E. coli infection of liver cysts
» BREAKPOINTS: A SHORT HISTORY AND OVERVIEW
» PHARMACODYNAMIC RELATIONSHIPS AND EMERGENCE OF RESISTANCE
» EVALUATION OF THE ANTIMICROBIAL RESISTANCE SURVEILLANCE DATA PUBLISHED IN THE MEDICAL LITERATURE
» PRACTICAL ASPECTS OF THE IMPLEMENTATION OF THE SURVEILLANCE PROGRAM
» Multivariate analysis methods
» Evolutionary genetic approaches
» Study of the relationship between bacterial resistance and antimicrobial consumption
» To predict the short-term evolution of resistance
» To evaluate interventions to control antibiotic resistance
» DISINFECTANTS: TYPES, ACTIONS, AND USAGES
» Evidence of bacterial resistance to biocides
» Mechanisms of bacterial resistance to biocides
» EVIDENCE OF CROSS-RESISTANCE BETWEEN BIOCIDES AND ANTIBIOTICS
» DISINFECTANT USAGE AND ANTIBIOTIC RESISTANCE
» METHODS OF LITERATURE REVIEW
» PROBLEMS WITH INTERPRETATION OF PUBLISHED STUDIES
» Distribution of educational materials
» Audit and feedback with or without other educational materials
» Educational group meetings or seminars
» Educational outreach/academic detailing
» Financial/healthcare system changes
» EFFECT OF INTERVENTIONS ON ANTIBIOTIC RESISTANCE
» DDD/1,000 INHABITANTS AND DAY (DID)
» PRESCRIPTIONS/1,000 INHABITANTS AND YEAR
» INDICATIONS FOR ANTIBIOTIC PRESCRIPTIONS
» POSSIBLE CAUSES FOR OBSERVED VARIATIONS IN ANTIBIOTIC USE
» DETERMINANTS OF ANTIBIOTIC CONSUMPTION
» COLLECTIVE AWAKENING AND PROGRESSIVE MOBILIZATION OF FRENCH PUBLIC HEALTH AUTHORITIES
» ANTIBIOTIC USE AND COST TRENDS
» IMPACT ON HEALTH BUDGETS OF ANTIBIOTIC USE
» ACCESS TO ESSENTIAL ANTIBIOTICS AT ALL LEVELS OF CARE
» EPIDEMIOLOGY OF ANTIMICROBIAL RESISTANCE
» THREAT OF ANTIMICROBIAL RESISTANCE
» ECONOMIC IMPLICATIONS OF ANTIMICROBIAL RESISTANCE
» FACTORS CONTRIBUTING TO DEVELOPMENT AND SPREAD OF RESISTANCE
» STRATEGIES FOR CONTAINMENT OF RESISTANCE IN DEVELOPING COUNTRIES
» Antibacterial resistance and policies
» Policies, guidelines, and education on antibacterial use
» Discovery, development, and commercialization in the face of policies
» Antibacterial development, labelling, and benefits
» WHAT CAN BE DONE NOW ABOUT ANTIBIOTIC RESISTANCE?
» HOW CAN THE DIAGNOSTIC LABORATORY HELP?
Show more